Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Ibexx who wrote (2259)	11/8/1997 10:14:00 PM
From: Cacaito	Respond to of 23519

A temporary drop is what I had in mind when I made this comment. Vivus drop will also be temporary. Vivus one product problem is well known. Pfizer "other blockbusters" like raloxifene for 99 is challenged by the early 98 expectation for Eli Lilly's draloxifene. AMH has a similar molecule for the osteoporosis business. BigKNY3, despite many important posters in PFE Motley Fool the fact is little data is known from PFE. I do not think this is the usual secretiveness of a company with a trade secret to protect. Maybe an stock price to protect?. Plenty of good companies with open research results (AMGN,LGND,Guilford and even Vivus). But, my interest is viagra, not the rest of Pfizer. Maybe when data on viagra is out I will invest in PFE, not now.